Intra-Articular Polyacrylamide Hydrogel Injections Improve Pain and Function in Knee Osteoarthritis

CompletedOBSERVATIONAL
Enrollment

387

Participants

Timeline

Start Date

February 11, 2023

Primary Completion Date

June 24, 2025

Study Completion Date

June 24, 2025

Conditions
Knee OsteoarthritisOsteoarthritisOsteoarthritis of the KneeDegenerative Joint Disease of the Knee
Interventions
BIOLOGICAL

Polyacrylamide hydrogel 2.5% intra-articular injection

A single intra-articular injection of 2.5% cross-linked polyacrylamide hydrogel (iPAAG), composed of 2.5% polyacrylamide and 97.5% non-pyrogenic water. The product (Arthrosamid®, Contura, Denmark) was administered under ultrasound guidance into the knee joint. Patients were followed retrospectively for 12 months to evaluate safety and effectiveness in reducing pain (VAS) and improving function (WOMAC).

Trial Locations (1)

Unknown

Hacettepe University, Faculty of Medicine, Department of Sports Medicine, Ankara

All Listed Sponsors
collaborator

Dr. Özgür Oktay Nar Private Clinic, Bursa, Türkiye

UNKNOWN

collaborator

Contura International A/S, Copenhagen, Denmark

UNKNOWN

collaborator

Bursa City Hospital, Bursa, Türkiye

UNKNOWN

lead

Feza Korkusuz MD

OTHER